Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control

Abstract

Radium-223 (223Ra) dichloride is an approved intravenous radiotherapy for patients with osseous metastases from castration-resistant prostate cancer (CRPC). In addition to the therapeutic alpha radiation, there is additional 223Ra radiation generated which produces photons that can be imaged with conventional gamma cameras. No studies have evaluated real-time and quality imaging during intravenous 223Ra administration to verify systemic circulation and exclude 223Ra extravasation at the injection site. A retrospective review was performed for fifteen 223Ra administrations for CRPC patients which were imaged using a large field of view portable gamma camera (LFOVPGC) for the purposes of quality control and patient safety. Dynamic imaging of the chest was performed before, during, and after the 223Ra administration to verify systemic circulation, per institutional clinical protocol. Before and after 223Ra administration, a static image was obtained of the intravenous access site. Dynamic imaging of the chest confirmed systemic administration early during the 1-minute injection period for all patients. There were no cases of focal 223Ra extravasation at the site of intravenous access. These results verify that systemic 223Ra administrations can be quantified with real-time imaging using an LFOVPGC. This simple approach can confirm and quantify systemic circulation of 223Ra early during injection and exclude focal extravasation for the purposes of quality control.

Chadwick L. Wright 1 and J. Paul Monk III 2 and Douglas A. Murrey Jr. 1 and Nathan C. Hall 1

Academic Editor:Shekhar Kumta

1, Department of Radiology, The Ohio State University Wexner Medical Center, 410 West Tenth Avenue, Columbus, OH 43210, USA
2, Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 410 West Tenth Avenue, Columbus, OH 43210, USA

Received 13 October 2014; Accepted 24 January 2015; 18 February 2015

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Targeted radiotherapy is a technique for treating primary malignancies and metastatic disease with intravascular administration of therapeutic radioisotopes, peptides, antibodies, and microspheres. ²²³ Ra dichloride is approved for intravenous radiotherapy for patients with osseous metastases from castration-resistant prostate cancer (CRPC). ²²³ Ra is an alpha-particle emitting radioisotope that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover, such as osseous metastases. ²²³ Ra has a half-life of 11.4 days. Osseous metastases from CRPC are amenable to targeted radiotherapy using ²²³ Ra and have the advantage of maximizing local alpha radiation effects to osseous metastases while minimizing radiation toxicity to adjacent normal bone and soft tissues [1, 2]. All patients referred for ²²³ Ra radiotherapy must initially be evaluated for verification of osseous metastases using intravenous Technetium-99m [figure omitted; refer to PDF] MDP bone scintigraphy or intravenous sodium fluoride-18 (Na¹⁸ F) PET/CT to insure eligibility for therapy [3, 4]. A complete course of ²²³ Ra dichloride radiotherapy involves intravenous administration of ²²³ Ra every 4 weeks for 6 cycles. Most of the radioactivity produced by ²²³ Ra results from the production of therapeutic alpha particles which travel only a very short distance in bone but are sufficiently energetic for therapeutic benefit. There is additional radiation generated by ²²³ Ra which produces photons (i.e., 81 and 84 keV) that have potential to be imaged using routine clinical nuclear medicine imaging [1, 3, 5]. To date, no studies have evaluated real-time and quality imaging during intravenous ²²³ Ra administration to verify systemic circulation and exclude ²²³ Ra extravasation at the injection site.

2. Materials and Methods

This retrospective study was approved by the Institutional Review Board at the Ohio State University Wexner Medical Center (OSUWMC). Between October 2013 and January 2014, 15 radiotherapy administrations of ²²³ Ra dichloride for 8 CRPC patients were performed and imaged using an institutional PGC imaging protocol for the purposes of quality control and patient safety. All 8 patients had received at least one prior administration of ²²³ Ra.

2.1. Imaging Protocol

The imaging protocol utilized an LFOVPGC (DIGIRAD Ergo, DIGIRAD Corporation, Poway, CA, USA) operating under the Xenon-133 setting (photopeak of 81 keV with a 10% window) with a 128 × 128 matrix for preinjection and postinjection ²²³ Ra planar and dynamic imaging. Low energy all purpose (LEAP) collimation was used. All images were subsequently processed using a Philips EBW workstation.

2.2. Preinjection Imaging

Prior to injection, a 1-minute static image of the background activity in the injection room was obtained as well as 1-minute static images of the patient's capped syringe containing the treatment dose and the patient's anterior chest (Figure 1). The purpose was to confirm the presence of detectable ²²³ Ra activity in syringe prior to injection and obtain background activity level assessments of the injection room and the patient's anterior chest before administration. The total preinjection LFOVPGC imaging time was 3 minutes (1 minute per image).

Preinjection LFOVPGC imaging (one minute per image) of the injection room background (left), capped syringe containing the ²²³ Ra dose (middle), and anterior chest background (right). The LFOVPGC detector head is represented by either a gray trapezoid or gray square just overlying the imaging target.

(a) [figure omitted; refer to PDF]

(b) [figure omitted; refer to PDF]

(c) [figure omitted; refer to PDF]

2.3. Dynamic Imaging during Injection

At the start of intravenous administration of ²²³ Ra, dynamic imaging of the anterior chest was obtained at 6 seconds/frame for 5 minutes in order to image the angiographic phase during the entire injection and subsequent 3 saline flushes (Figure 2). The camera was allowed to acquire data for approximately 15-30 seconds before the IV administration began. The total dynamic LFOVPGC imaging time was 5 minutes for the dynamic imaging of the therapeutic IV administration.

Figure 2: Dynamic LFOVPGC imaging of the anterior chest during intravenous administration of ²²³ Ra and subsequent saline flushes (5-minute continuous imaging 6 sec/frame).

[figure omitted; refer to PDF]

2.4. Postinjection Imaging

Following slow IV injection of ²²³ Ra and removal of the dedicated IV access, 1-minute static images, each of the patient's IV injection site and the capped empty syringe, were obtained (Figure 3). The purpose of these images was to confirm the presence or absence of any residual ²²³ Ra activity in syringe or syringe cap after injection and to assess any gross extravasation of ²²³ Ra at the IV injection site. The total postinjection LFOVPGC imaging time was 2 minutes (one minute per image).

Postinjection LFOVPGC imaging of the capped empty syringe (left, 1 minute) and IV injection site (right, 1 minute).

(a) [figure omitted; refer to PDF]

(b) [figure omitted; refer to PDF]

2.5. Statistics

Unless otherwise indicated, all values are expressed as mean ± standard deviation. Linear regression analysis of LFOVPGC counts and syringe ²²³ Ra activity was performed using JMP Pro 10.0.2 (SAS Institute, Inc.).

3. Results and Discussion

The average ± standard deviation for the ²²³ Ra dichloride doses administered intravenously was [figure omitted; refer to PDF] kBq ( [figure omitted; refer to PDF] , range 3848-5994 kBq). During preinjection LFOVPGC imaging (Figure 4), the average injection room background activity was [figure omitted; refer to PDF] counts ( [figure omitted; refer to PDF] , range 916-1183 counts). The average background-corrected preinjection syringe activity was [figure omitted; refer to PDF] counts ( [figure omitted; refer to PDF] , range 209633-389084 counts). There were two radiotherapy administrations (out of 15) in which the delivered ²²³ Ra dichloride doses were provided in two syringes instead of one syringe (not shown and excluded from subsequent quantitative dynamic imaging analyses of the anterior chest). The average anterior chest background activity was [figure omitted; refer to PDF] counts ( [figure omitted; refer to PDF] , range 1016-2903 counts). The increased background counts for the anterior chest relative to the background counts for the injection room are consistent with the fact that all patients had received at least one prior ²²³ Ra radiotherapy administration. This implies that ²²³ Ra from the last radiotherapy administration had been incorporated into the osseous structures within the anterior chest field of view (presumably within osseous metastases) and some residual incorporated ²²³ Ra was still detectable on the preinjection chest imaging. The average absolute difference in anterior chest and background activities was [figure omitted; refer to PDF] ( [figure omitted; refer to PDF] , range 9-1878 counts).

Figure 4: Preinjection LFOVPGC imaging of the injection room background (top left), capped syringe containing the ²²³ Ra dose (top middle), and anterior chest background (top right). Total LFOVPGC counts for the entire field of view are provided for these 1-minute acquisitions (top row).

[figure omitted; refer to PDF]

Dynamic LFOVPGC images of the anterior chest were compressed into 30-second frames (Figure 5). In all cases, dynamic imaging of the chest confirmed systemic administration early during the 1-minute injection period. Quantitative region-of-interest (ROI) analysis of the dynamic anterior chest imaging confirmed that the time-to-peak ²²³ Ra activity was at least 1 minute for all radiotherapy administrations. ROIs were drawn around the heart and entire anterior chest field of view (including the heart) and total activity counts for each 30-second frame were measured. Dynamic ROI analysis confirmed that the time-to-peak ²²³ Ra activity was at least 1 minute in all 13 single-syringe radiotherapy administrations (Figure 6).

Figure 5: Dynamic images of the anterior chest during injection of 3848 kBq ²²³ Ra via a right antecubital fossa IV site. Dynamic images were compressed into 30-second frames. First 30-second frame is in the upper left and progresses from left to right and top to bottom.

[figure omitted; refer to PDF]

Figure 6: Average total activity counts for the heart and anterior chest ROIs for all 13 radiotherapy administrations using only single-syringe doses ( [figure omitted; refer to PDF] ). Quantitative ROI analysis confirmed systemic administration early during the 1-minute injection period and the time-to-peak ²²³ Ra activity was at least 1 minute.

[figure omitted; refer to PDF]

During postinjection LFOVPGC imaging (Figure 7), the average ± standard deviation for the background-corrected postinjection syringe activity was [figure omitted; refer to PDF] counts ( [figure omitted; refer to PDF] , range 2656-4644 counts). The measured residual ²²³ Ra activity was 37 kBq in all syringes and incidentally all residual activity localized to the syringe cap on imaging. Background-corrected preinjection and postinjection syringe activity positively correlated with the corresponding preinjection and postinjection syringe dose activity measurements ( [figure omitted; refer to PDF] , [figure omitted; refer to PDF] ) (see the following equation): [figure omitted; refer to PDF] There were no instances of focal ²²³ Ra extravasation at the site of intravenous access (Figure 8). Given that 37 kBq of residual ²²³ Ra activity within a syringe cap produced a discrete focus of activity on LFOVPGC imaging and that the vast majority of IV sites are superficially located (i.e., minimal soft tissue attenuation), it is likely that any focal extravasation of ≥37 kBq would be detectable at the IV site.

Figure 7: Preinjection LFOVPGC imaging of a capped syringe containing the ²²³ Ra dose (top left) and subsequent postinjection imaging of the capped empty syringe (top right). There is a single discrete focus of activity in the capped empty syringe corresponding to 37 kBq of residual ²²³ Ra activity within the syringe cap. Total LFOVPGC counts for the entire field of view are provided for these 1-minute acquisitions (top row).

[figure omitted; refer to PDF]

Figure 8: Postinjection LFOVPGC imaging of the patient's IV injection site (bottom, one-minute acquisition). A white outline of the patient's body contour has been manually superimposed on the bottom LFOVPGC image which demonstrates no evidence of focal ²²³ Ra extravasation in the right antecubital fossa injection site but rather systemic ²²³ Ra activity within the partially imaged chest and abdomen. Total LFOVPGC counts for the entire field of view are provided for this 1-minute acquisition (bottom).

[figure omitted; refer to PDF]

4. Conclusions

The demand for ²²³ Ra dichloride is anticipated to increase significantly in the foreseeable future with potential expansion into women with osseous metastatic disease from breast cancer. Our results demonstrate that (1) systemic ²²³ Ra administrations in CRPC patients can be dynamically imaged using a clinical LFOVPGC imaging system and (2) systemic ²²³ Ra administrations can be further quantified with this real-time LFOVPGC imaging approach. Total time for this LFOVPGC imaging protocol is 10 minutes and the total patient imaging time is 7 minutes. This simple imaging approach can be used to quickly confirm and quantify systemic circulation of ²²³ Ra during injection as well as evaluate focal soft tissue extravasation at the IV site for the purposes of patient safety and quality control.

Although no cases of focal soft tissue extravasation were identified in this study, our results indicate that injection site imaging could rapidly quantify focally extravasated ²²³ Ra activity for subsequent monitoring and dosimetry. Serial imaging of the injection site (e.g., right antecubital fossa) and the contralateral noninjected limb (i.e., left antecubital fossa) would allow for quantitative assessment of ²²³ Ra resorption and confirm when complete resorption was achieved (i.e., ²²³ Ra activity in the injected limb approximates the activity in contralateral noninjected limb).

This real-time LFOVPGC assessment of the patient, dose, and injection site is a simple adjunct to routine survey meter evaluation by radiation safety or medical physics. There is sparse literature on the role of gamma camera imaging for quality assessment of intravenous radiotherapy administration. One study demonstrated the feasibility of gamma camera imaging to qualitatively assess Yttrium-90 bremsstrahlung activity using a phantom simulation of intravenous Yttrium-90-labeled antibody extravasation [6]. Thus, real-time LFOVPGC imaging can be easily adapted for real-time quality assessment of other radionuclide therapy administrations such as gamma-emitting intravenous radiotherapies (e.g., Samarium-153, Iodine-131 metaiodobenzylguanidine), bremsstrahlung-emitting intravenous radiotherapies (e.g., Strontium-90, Yttrium-90-labeled antibodies/peptides), and bremsstrahlung-emitting intra-arterial radioembolization therapies (e.g., Yttrium-90 containing resin or glass microspheres).

It remains to be determined in a prospective clinical trial throughout the course of ²²³ Ra radiotherapy if there is any prognostic significance to serial quantitative assessment of the difference in measured residual activity between preinjection anterior chest and the background activity of the injection room (e.g., patients with significantly higher preinjection residual activity demonstrate improved clinical outcomes when compared with those patients with little or no preinjection residual activity).

Acknowledgments

The authors would like to thank Nichole Storey, MSHS, Angie Dado, Alicia Gould, and Michelle Bowen for their assistance.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] O. Sartor, P. Hoskin, Ø. S. Bruland, "Targeted radio-nuclide therapy of skeletal metastases," Cancer Treatment Reviews , vol. 39, no. 1, pp. 18-26, 2013.

[2] C. Parker, O. Sartor, "Radium-223 in prostate cancer," The New England Journal of Medicine , vol. 369, no. 17, pp. 1659-1660, 2013.

[3] S. Nilsson, R. H. Larsen, S. D. Fossa, L. Balteskard, K. W. Borch, J.-E. Westlin, G. Salberg, Ø. S. Bruland, "First clinical experience with α -emitting radium-223 in the treatment of skeletal metastases," Clinical Cancer Research , vol. 11, no. 12, pp. 4451-4459, 2005.

[4] E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, I. Leibovitch, "The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT," Journal of Nuclear Medicine , vol. 47, no. 2, pp. 287-297, 2006.

[5] C. Hindorf, S. Chittenden, A.-K. Aksnes, C. Parker, G. D. Flux, "Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases," Nuclear Medicine Communications , vol. 33, no. 7, pp. 726-732, 2012.

[6] S. M. Rhymer, J. A. Parker, M. R. Palmer, "Detection of 90Y extravasation by bremsstrahlung imaging for patients undergoing 90Y-ibritumomab tiuxetan therapy," Journal of Nuclear Medicine Technology , vol. 38, no. 4, pp. 195-198, 2010.